CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
CorEvitas · NCT06238765
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 10–15 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 1500
- US sites recruiting
- 1
- Study start
- December 2, 2023
- Record last updated
- June 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
Conditions: Atopic Dermatitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- To be eligible to participate in this registry, an individual must meet all the following criteria:
- Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified healthcare provider
- Is 10 - 15 years of age at the time of enrollment.
- Subject has initiated or is initiating an enrollment-eligible medication at the time of enrollment
Exclusion Criteria
- An individual who meets any of the following criteria will be excluded from participation in the registry:
- Is participating or planning to participate in a blinded clinical trial for an AD drug.
- Is unwilling or unable to provide standing height measurements.
Recruiting US locations
CorEvitas, LLC
Waltham, MA 02451
Site contact: Cathy Cheney · 508-555-1212 · corevitasregistrytrials@corevitas.com
Similar studies in Massachusetts
All dermatology studies in Massachusetts →- RecruitingHealthy volunteers
AVAVA MIRIA General Use
AVAVA, Inc.
- Location
- Waltham, MA
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Boston, MA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Boston, MA + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Brighton, MA + 90 other US sites
- Eligibility basics
- Ages 40+